• Join
  • Login
  • Contact

Search abstracts / presentations

Role of bisphosphonates in osteoporosis

  • In: Osteoporosis And Fractures (SIGs Nuclear/Radiologic Pharmacy and Pharmacoeconomics/Pharmacoepidemiology) on Wednesday, 8 September 2004, 9:00-12:00
  • At: New Orleans (USA) (2004)
  • Type: Presentation
  • By: ROSEN, Clifford (St. Joseph Hospital, Maine Center for Osteoporosis Research, Bangor, United States of America)
  • Abstract:

    Bisphosphonates, have revolutionized the treatment of metabolic bone diseases. Etidronate was a first generation agent used to treat heterotopic ossification and Paget’s disease. Its availability prompted off label use of this drug for osteoporosis. Trials have shown that etidronate increases BMD and reduces spine fractures. Alendronate was the


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses